Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections

  • Pinkus Tober-Lau
  • Henning Gruell
  • Kanika Vanshylla
  • Willi M Koch
  • David Hillus
  • Philipp Schommers
  • Isabelle Suárez
  • Norbert Suttorp
  • Leif Erik Sander
  • Florian Klein
  • Florian Kurth

Related Research units

Abstract

To determine neutralizing activity against the severe acute respiratory syndrome coronavirus 2 ancestral strain and 4 variants of concern, we tested serum from 30 persons with breakthrough infection after 2-dose vaccination. Cross-variant neutralizing activity was comparable to that after 3-dose vaccination. Shorter intervals between vaccination and breakthrough infection correlated with lower neutralizing titers.

Bibliographical data

Original languageEnglish
ISSN1080-6040
DOIs
Publication statusPublished - 05.2022
PubMed 35259088